Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

By P. Hillmen, A. Skotnicki, T. Robak, B. Jakšić, A. Dmoszyńska, Jingyang J. Wu, C. Sirard, J. Mayer. Journal of Clinical Oncology, 2007

607 citations recorded by the source corpus.

Subfields: Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/842a672677a3fe2c8ee602274a3a3b25b3d46801

Citations in the corpus

• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, neutral): “#11 g/dL, n (%) 11 (35) 42 (42) 53 (40)”
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “Neutropenia 84 (35) 18 (16) 60 (27) 18 (16) 111 (33) 91 (28)”